Remimazolam for long-term sedation during invasive mechanical ventilation in critically ill patients

Remimazolam for long-term sedation during invasive mechanical ventilation in critically ill patients - Remimazolam in ICU patients

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON57010

Enrollment

Registered

2024-09-12

Start date

2024-10-18

Completion date

Unknown

Last updated

2025-09-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ICU patients on a ventilator Mechanical ventilated ICU patients

Interventions

In this intervention trial eligible patients will receive remimazolam for long-term sedation. Any sedatives, i.e. propofol 0-4 mg/kg/h, and analgesics, i.e. sufenta 5-20 µg/h, used before study enro

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: *Admission to the ICU of the Elisabeth-TweeSteden Ziekenhuis *Age 18 years or older *Invasive mechanical ventilation *Target RASS -3 to -5 *Expected stay in the ICU > 3 days *Renal failure according to KDIGO criteria (eGFR

Exclusion criteria

Exclusion criteria: *Traumatic brain injury with deep sedation (RASS -5), aneurysmal subarachnoid hemorrhage with Glasgow Coma scale

Design outcomes

Primary

Measure	Time frame
The ICU length of stay (in 24h periods) in critically ill patients with renal failure treated with a sedation regimen with remimazolam, compared to patients with renal failure treated with a sedation regimen with midazolam.	—

Secondary

Measure	Time frame
Duration to Richmond Agitation Sedation Scale (RASS) 0/-1 after cessation of remimazolam or midazolam Duration of invasive mechanical ventilation Cumulative dose of vasopressors during stay in the ICU Delirium after cessation of remimazolam or midazolam Hospital LOS ICU mortality *Hospital mortality	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)